Heparin
Calciparine, Defencath, Embolex, Heparin (heparin) is an unknown pharmaceutical. Heparin was first approved as Calciparine on 1982-01-01. It is used to treat cerebral infarction, coronary thrombosis, myocardial infarction, postoperative complications, and pulmonary embolism amongst others in the USA. The pharmaceutical is active against antithrombin-III. In addition, it is known to target epidermal growth factor receptor and receptor tyrosine-protein kinase erbB-4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Defencath (discontinued: Embolex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dihydroergotamine mesylate
+
Heparin sodium
+
Lidocaine hydrochloride
Heparin calcium
Heparin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019952 RX | 1992-07-20 | 1 products, RLD, RS |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | B. Braun Medical | N-019952 RX | 1992-07-20 | 2 products, RLD, RS |
| HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | B. Braun Medical | N-019953 RX | 2023-12-15 | 1 products, RLD, RS |
| HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | B. Braun Medical | N-019953 RX | 1992-07-20 | 1 products, RLD, RS |
| HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Baxter | N-018609 RX | 1982-04-28 | 1 products |
| HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | Baxter | N-018609 RX | 1982-04-28 | 1 products |
| HEPARIN SODIUM | Fresenius Kabi | N-017029 RX | 2011-03-31 | 1 products, RLD, RS |
| HEPARIN SODIUM PRESERVATIVE FREE | Fresenius Kabi | N-017029 RX | 1986-04-28 | 2 products, RLD, RS |
| HEPARIN SODIUM IN PLASTIC CONTAINER | Fresenius Kabi | N-017029 RX | 1985-12-05 | 4 products, RLD, RS |
| HEPARIN SODIUM | Fresenius Kabi | N-017029 RX | 1982-01-01 | 3 products, RLD, RS |
Show 12 marketed
Show 58 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| defencath | New Drug Application | 2023-12-21 |
| heparin | unapproved drug other | 2012-08-09 |
| heparin sodium | unapproved drug other | 2014-12-24 |
| heparin sodium | New Drug Application | 2024-01-29 |
| heparin sodium and dextrose | New Drug Application | 2023-12-04 |
| heparin sodium and sodium chloride | New Drug Application | 2019-04-19 |
| heparin sodium in dextrose | New Drug Application | 2023-07-27 |
| heparin sodium in sodium chloride | New Drug Application | 2024-01-27 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
HEPARIN SODIUM / TAUROLIDINE, DEFENCATH, CORMEDIX | |||
| 2033-11-15 | GAIN | ||
| 2028-11-15 | NCE | ||
ATC Codes
B: Blood and blood forming organ drugs
— B01: Antithrombotic agents
— B01A: Antithrombotic agents
— B01AB: Heparin group antithrombotic drugs
— B01AB01: Heparin
— B01AB51: Heparin, combinations
— B01AC: Platelet aggregation inhibitors excl. heparin
— B01AC30: Platelet aggregation inhibitor combinations excl. heparin
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05B: Antivaricose therapy drugs
— C05BA: Heparins or heparinoids for topical use
— C05BA03: Heparin
— C05BA53: Heparin, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01X: Other ophthalmologicals in atc
— S01XA: Other ophthalmologicals in atc
— S01XA14: Heparin
HCPCS
Code | Description |
|---|---|
| B4216 | Parenteral nutrition; additives (vitamins, trace elements, heparin, electrolytes), home mix, per day |
| E1520 | Heparin infusion pump for hemodialysis |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units |
| J1644 | Injection, heparin sodium, per 1000 units |
| S2120 | Low density lipoprotein (ldl) apheresis using heparin-induced extracorporeal ldl precipitation |
| S9336 | Home infusion therapy, continuous anticoagulant infusion therapy (e.g., heparin), administrative services, professional pharmacy services, care coordination and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem |
| S9372 | Home therapy; intermittent anticoagulant injection therapy (e.g., heparin); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem (do not use this code for flushing of infusion devices with heparin to maintain patency) |
Clinical
Clinical Trials
1423 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 3 | 9 | 38 | 19 | 37 | 104 |
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 2 | 8 | 24 | 22 | 34 | 88 |
| Covid-19 | D000086382 | — | U07.1 | 5 | 20 | 25 | 11 | 23 | 72 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | 4 | 3 | 18 | 23 | 17 | 64 |
| Thrombosis | D013927 | — | — | 3 | 6 | 8 | 9 | 24 | 49 |
| Neoplasms | D009369 | — | C80 | 3 | 5 | 12 | 3 | 20 | 42 |
| Coronary artery disease | D003324 | — | I25.1 | — | 7 | 2 | 11 | 21 | 41 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 3 | 9 | 12 | 8 | 32 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 2 | 1 | 4 | 23 | 30 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 1 | 3 | 7 | 7 | 12 | 30 |
Show 117 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Septic shock | D012772 | — | A48.3 | 1 | 3 | 2 | — | 13 | 19 |
| Healthy volunteers/patients | — | — | — | 13 | 1 | 1 | — | 1 | 15 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 2 | 4 | — | 8 | 14 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 3 | 3 | 2 | — | 3 | 11 |
| Ischemia | D007511 | EFO_0000556 | — | 1 | 2 | 1 | — | 5 | 8 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 3 | 1 | — | 3 | 8 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | 4 | — | 3 | 8 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | 1 | 4 | — | 2 | 6 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 2 | — | 4 | 6 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 2 | 1 | — | 2 | 5 |
Show 63 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 2 | — | — | 11 | 13 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | 1 | — | — | 3 | 4 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | 3 | 4 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 2 | — | — | 1 | 4 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | 3 | 4 |
| Intracranial aneurysm | D002532 | EFO_0003870 | I67.1 | — | 1 | — | — | 3 | 4 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | 1 | 2 | — | — | — | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 1 | — | — | 1 | 2 |
| Patent foramen ovale | D054092 | HP_0001655 | Q21.12 | — | 1 | — | — | 1 | 2 |
| Iga vasculitis | D011695 | EFO_1000965 | D69.0 | 1 | 1 | — | — | 1 | 2 |
Show 36 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colonic neoplasms | D003110 | — | C18 | 1 | — | — | — | 1 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | 2 | — | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | — | — | 1 | 2 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 1 | — | — | — | 1 | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | — | — | — | 1 | 2 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | — | — | — | 1 | 2 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
| Nasopharyngeal neoplasms | D009303 | — | — | 1 | — | — | — | — | 1 |
Show 10 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary stenosis | D023921 | EFO_1000882 | — | — | — | — | — | 4 | 4 |
| Chest pain | D002637 | HP_0100749 | R07.9 | — | — | — | — | 4 | 4 |
| Carotid stenosis | D016893 | — | — | — | — | — | — | 3 | 3 |
| Cytokine release syndrome | D000080424 | — | D89.83 | — | — | — | — | 3 | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 3 | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 3 | 3 |
| Brain ischemia | D002545 | EFO_0003883 | I67.82 | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | — | — | — | 2 | 2 |
| Fertilization in vitro | D005307 | — | — | — | — | — | — | 2 | 2 |
Show 138 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Heparin |
| INN | heparin sodium |
| Description | Heparin, also known as unfractionated heparin (UFH), is a medication and naturally occurring glycosaminoglycan. Heparin is a blood anticoagulant that increases the activity of antithrombin. It is used in the treatment of heart attacks and unstable angina. It can be given intravenously or by injection under the skin. Its anticoagulant properties make it useful to prevent blood clotting in blood specimen test tubes and kidney dialysis machines.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 9005-49-6 |
| RxCUI | 5224 |
| ChEMBL ID | CHEMBL1909300 |
| ChEBI ID | — |
| PubChem CID | 22833565 |
| DrugBank | DB01109 |
| UNII ID | ZZ45AB24CA (ChemIDplus, GSRS) |
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
EGFR
EGFR
ERBB4
ERBB4
Organism
Homo sapiens
Gene name
EGFR
Gene synonyms
ERBB, ERBB1, HER1
NCBI Gene ID
Protein name
epidermal growth factor receptor
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b) oncogene homolog, cell growth inhibiting protein 40, cell proliferation-inducing protein 61, EGFR vIII, epidermal growth factor receptor tyrosine kinase domain, erb-b2 receptor tyrosine kinase 1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
Uniprot ID
Mouse ortholog
Egfr (13649)
epidermal growth factor receptor (Q01279)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Heparin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 276,338 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30,049 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use